I mean let’s get real about this subred.
Anyone with a portfolio of $1M+ will unlikely be trading on single name stocks.
Look, I’m sure there are folks who have done what the subred founder did, but most retail investors with that much capital is risk averse.
Really the “race” is to $1M and then start improving your source of income to hit $10M net worth.
Don’t be delusional and lose all your capital on single stocks.
For anyone that have been thinking ahead of the earnings today either it would go up or down, then you will check this news as it explains what an investor or traders could check out before placing any buy or sell.
It also talks about NVDA, either it is a smart long term stock someone could buy and trade on stock futures to make good profit.
Looking for general feedback on my portfolio structure.
I feel like I may have too many individual positions, and I’m considering simplifying over time by trimming lower-conviction names and moving more into higher-conviction holdings or broader ETFs.
I made a holdings carousel sorted roughly largest to smallest. I removed account details, share quantities, and personal info.
Main questions:
Does this look too scattered?
Are there obvious sector concentration issues?
Which types of positions would you clean up first?
Would you consolidate smaller 1%–ish positions into ETFs or higher-conviction names?
Is this too many individual holdings for a long-term portfolio?
I’m not looking for personalized financial advice — just general feedback on structure, concentration, and cleanup ideas.
Thanks. Honest feedback appreciated.
Hey guys, if you missed it, CytoDyn just settled $500K with investors over claims it misled the market about its drug leronlimab some time ago. And they have already sent the agreement to the court for final approval.
In a nutshell, in 2021, CytoDyn was accused of overstating the effectiveness and regulatory progress of leronlimab. In short, the FDA later said the company’s claims were not supported by data, revealing no clear benefit.
After this news came out, the stock dropped 25%, and investors filed a lawsuit for their losses.
The good news is that the company recently agreed to settle $500K with them, and already sent this agreement to the court for final approval. So, if you invested in $CYDY when all of this happened, you can check the details and file your claim here.
Anyway, has anyone here invested in $CYDY at that time? How much were your losses, if so?
Most people who followed $CYDY remember March 30, 2021. The FDA publicly stated that CytoDyn's claims about leronlimab were "misleading and not supported by the data", no benefit was shown in COVID-19 treatment trials. The stock dropped 25%+ that day.
What happened afterward was a class action lawsuit covering investors who held $CYDY between March 27, 2020 and March 30, 2022.
A $500,000 settlement has been reached and terms are now submitted to the court for approval.
Who qualifies?
Anyone who held $CYDY during the class period and suffered losses from the alleged misrepresentations about leronlimab's effectiveness for HIV and COVID-19.
Can I still apply?
Yes, you can submit your application now and it will be processed once claims filing officially opens after court approval.
If you were damaged by this don't forget to check your eligibility. GL!
Taco’s portfolio is back over 65k now thanks to the strong performance in Oscar Health. Even with Ethereum performing as badly as it has, my port’s still up over 20% this past month which is impressive.
I did take some gains off the table here and sold 2 of my January 2027 $18C on Oscar for a 115% gain. I’ve learned my lesson a time or two with Oscar trading between the $12-$22 range and even with a strong earnings report behind them, and seemingly breaking out into their best days ahead, — given how poorly ETH has performed I took the gains here. I’m riding the last one here to Valhalla though which you can see in the last screenshot.
I also traded out of one other position this week and that was WhiteFiber WYFI. I sold 2 $17.5C against them expiring last Friday and needless to say I got burnt on those. It’s ok though as I am losing conviction in the managements ability to be transparent and deliver to shareholders regardless of the current market hype cycle we’re in around the AI build out. I was done with WYFI and still made out profitable. I still have my position in BTBT buts its also on notice in my portfolio given managements poor decision history here.
Often when I start to lose conviction in a play I will sell calls against it and collect the premium until I get called away. This time it was WYFI’s turn.
What do you think of Taco’s latest moves?
I like the nuclear SMR story and the long-term clean energy angle, but it still feels really early and priced like a lot goes right. No real revenue yet and plenty of execution risk. Curious if people are holding this for the long game or taking profits before the hype fades.
The Price Target raise comes after the amazing results DRTS shared from the Recurring GBM trial, achieving Complete Response in one of the toughest to treat and most high unmet needs cancers, that has no other options and no standard of care.
The analyst points out the specific GBM potential, but also that this success further proves the potential of DRTS as a multi-indication platform.
The timing couldn’t be better, with the ASCO annual meeting coming up, where DRTS will present and is expected to share Pancreatic Cancer Survival Data. This kind of data alone added 10 Billion to RVMD’s market cap, with the DRTS data expected to be even better.
DRTS also completed its cSCC Pivotal Trial (aka phase 3 is behind them), with the next step being FDA submission for approval of Skin cancer which is already approved by the PMDA in Japan.
Citi analysts said: “We believe DRTS shares could rise into the readouts as investors better appreciate Alpha DaRT’s multi-indication potential.”
Those readouts include the full GBM trial results, the US FDA IMPACT Pancreatic Cancer trial results, the cSCC Pivotal trial results, and maybe the most exciting is the combination therapy trial with Keytruda, among others all coming in the coming months.
NFA and DYOR, but imo this won’t be the last time we see DRTS price targets getting raised this year!
The AI Data Center Energy Crisis is HERE.
Billion-Dollar Trash Companies Have No Solution, But Hyliion’s Reactor Does
Long on HYLN
Hey everyone,
I’m building a closed-beta market intelligence dashboard and I’m trying to get feedback from people who actively follow crypto markets.
I want to be clear upfront: this is not financial advice, not copy trading, not trade execution, and not a “buy/sell signal” service.
The problem I’m trying to solve is more about workflow.
Crypto traders and investors usually have information scattered across a bunch of places:
I’m trying to build something that organizes market context better, especially around:
The goal is not to tell people what to buy. The goal is to make market research and watchlist tracking cleaner.
A few questions for people here:
I’m mostly looking for blunt feedback before inviting more beta users.
I’m watching NREDF on the 5-minute because the chart has a pretty clean imbalance sitting right above price.
This is not a random “hope it goes up” setup. The structure is clear.
Price is sitting near $1.54, and the imbalance zone I’m focused on is roughly $1.55 to $1.63. If buyers can reclaim $1.55 and hold it, I think the chart has room to start filling that pocket.
My first area is $1.60. That is the middle of the zone and the first place I would expect some reaction.
If momentum stays strong, the next magnet is $1.62 to $1.63. Above that, I’m watching $1.66 and $1.68 as the higher resistance targets.
The invalidation is also simple. If NREDF cannot hold $1.54 to $1.55, then the setup loses strength and I do not want to force it.
For me, this is a clean imbalance trade:
Reclaim $1.55, target $1.60, then $1.62 to $1.63. Stretch only if buyers keep control.
Not financial advice. Just the setup I’m watching.
The AI bottleneck might not be how many chips can be bought.
It might be how much power can actually be delivered.
S&P expects installed data center capacity to grow 3.6 times current capacity by 2040. AI training data centers are projected to grow 24% annually and add 170 GW of installed capacity by 2040 versus 2025.
That is a massive power infrastructure challenge.
S&P also says up to 30 GW of new data center capacity could be installed annually worldwide through 2030. That is roughly 15 new hyperscaler data centers per year, each averaging 2 GW and about $10 billion in capital expenditure.
Those facilities need transformers, substations, cooling, backup systems, switchgear, interconnects, and wiring.
This is where copper keeps showing up.
Not financial advice. AI may be a software story on the surface, but underneath it is a grid materials story
The latest NovaRed advisory-board appointment caught my attention because it highlights how different the copper sector looks now compared to older commodity cycles.
Jake Amsterdam’s background is heavily tied to international public policy, governance, investigations, advocacy, and strategic communications. That seems unusual until you step back and look at the broader copper market. The industry is no longer driven only by construction demand or industrial growth. Copper is now tied directly to AI infrastructure, electrification, defense systems, transmission networks, and supply-chain resilience.
When a commodity becomes strategically important, the surrounding issues become more important too. Governments start caring more about domestic supply, ESG standards, stakeholder engagement, permitting, and geopolitical alignment. Institutional investors also start evaluating companies differently.
That is why I think NRED / NREDF bringing in someone with cross-border governance and policy experience is more meaningful than it first appears. The company seems to understand that future copper projects may need not only technical credibility, but also reputational and political credibility.
Still early-stage and risky of course, but the broader strategy is interesting.